In a large cohort study of 1.3 million participants, both systolic and diastolic hypertension were associated with composite of MI, ischemic stroke and hemorrhagic stroke, independent of thresholds defining hypertension.
The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?
In a meta-analysis of 21 RCTs including diverse populations, supplementation with vitamin D did not result in a reduction of MACE, MI, stroke/CVA, CV mortality and all-cause mortality compared to placebo.
In the SMART population, smoking cessation after an event resulted in about 5 years longer survival and delay of recurrent events by about 10 years, compared to those who continue to smoke.
EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.
EuroPrevent 2019 Prof. Jacobs discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.
The European Association of Preventive Cardiology reviewed various online risk prediction algorithms and considers advantages and caveats, and gives guidance on which tool to use for which patient.
EuroPrevent 2019 Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.
In a follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.
EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.
Based on a large Dutch primary care database, lipid-lowering treatment declined with increasing age in subjects aged ≥70 years, with higher prescription in frail vs. non-frail older adults regardless of CVD at baseline.
The LIFE-CVD model can assess 10-year and lifetime CVD risk and life-years gained free from CVD and the effect of interventions in apparently healthy people.